AMRI and Proteros Biostructures have signed an agreement for a joint offering to the life sciences industry. Proteros will provide protein crystallization and X-ray structural analysis services that complement AMRI’s existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.

According to a joint statement, “Proteros’ expertise in structural biology services combined with AMRI’s expansive discovery and development capabilities provides biotechnology and pharmaceutical companies access to a portfolio of contract services from two companies known for their high level of expertise, dedication to quality and impressive track record of success.”

“We are excited about this new relationship that expands the depth and level of service we can offer to customers around the globe looking for integrated solutions from one point of service and contact,” said Thomas E. D’Ambra, Ph.D., AMRI’s chairman, president and chief executive officer.